Optimizing Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Risk‐Stratified Recursive Partitioning Analysis Based on 9th Edition Staging

Although induction chemotherapy (IC) in combination with concurrent chemoradiotherapy constitutes the standard treatment for locally advanced nasopharyngeal carcinoma (LANPC), the optimal number of IC cycles remains undetermined. The 9th edition staging system provides a refined risk stratification framework. We aimed to develop a prognostic tool to stratify patients with LANPC and define the optimal number of IC cycles for distinct risk groups based on new staging. We analyzed 1216 patients with LANPC treated with IC and employed propensity score matching to minimize bias. Progression-free survival (PFS) was the primary endpoint, analyzed using Kaplan-Meier curves. A recursive partitioning analysis (RPA) model was developed and validated for risk stratification. Survival outcomes and toxicities were compared across IC cycle groups. After a median follow-up of 56 months, 2- and 3-cycle IC yielded greater improvements in PFS compared with 4-cycle IC (p < 0.001). The RPA model incorporated 9th edition staging, pretreatment EBV DNA, and IC response, stratifying patients into three risk categories. For low-risk patients, 2- and 3-cycle IC yielded comparable PFS, both superior to 4-cycle IC (p < 0.001). In intermediate-risk patients, significantly higher 5-year PFS was achieved with 2-cycle IC than with 3- (73.4% vs. 56.2%, p = 0.014) or 4-cycle IC (73.4% vs. 47.5%, p < 0.001). High-risk patients benefited more from 3-cycle versus 2- (47.5% vs. 31.7%; p = 0.038) or 4-cycle IC (47.5% vs. 36.2%; p = 0.039). Overall, the RPA-based model effectively stratified risk, guiding individualized IC cycle selection. Balancing toxicity and efficacy, 2-cycle IC is optimal for the low- and intermediate-risk groups, while 3-cycle IC is preferred for the high-risk group.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2026-11-16
DOI
https://doi.org/10.1002/ijc.70819
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Optimizing Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Risk‐Stratified Recursive Partitioning Analysis Based on 9th Edition Staging

Lin JiaYing, Hai‐Qiang Mai, Ruiling Xie, Hao‐Yuan Mo et al.
5 links
International Journal of Cancer
Head and Neck Cancer Studies
article

Optimizing Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Risk‐Stratified Recursive Partitioning Analysis Based on 9th Edition Staging

Lin JiaYing, Hai‐Qiang Mai, Ruiling Xie, Hao‐Yuan Mo, Qiu-Yan Chen, Ting Liu, Jinjing Lu, Tianyi Wang, 蕭嘉士, Jieyi Lin
article en

Abstract

Although induction chemotherapy (IC) in combination with concurrent chemoradiotherapy constitutes the standard treatment for locally advanced nasopharyngeal carcinoma (LANPC), the optimal number of IC cycles remains undetermined. The 9th edition staging system provides a refined risk stratification framework. We aimed to develop a prognostic tool to stratify patients with LANPC and define the optimal number of IC cycles for distinct risk groups based on new staging. We analyzed 1216 patients with LANPC treated with IC and employed propensity score matching to minimize bias. Progression-free survival (PFS) was the primary endpoint, analyzed using Kaplan-Meier curves. A recursive partitioning analysis (RPA) model was developed and validated for risk stratification. Survival outcomes and toxicities were compared across IC cycle groups. After a median follow-up of 56 months, 2- and 3-cycle IC yielded greater improvements in PFS compared with 4-cycle IC (p < 0.001). The RPA model incorporated 9th edition staging, pretreatment EBV DNA, and IC response, stratifying patients into three risk categories. For low-risk patients, 2- and 3-cycle IC yielded comparable PFS, both superior to 4-cycle IC (p < 0.001). In intermediate-risk patients, significantly higher 5-year PFS was achieved with 2-cycle IC than with 3- (73.4% vs. 56.2%, p = 0.014) or 4-cycle IC (73.4% vs. 47.5%, p < 0.001). High-risk patients benefited more from 3-cycle versus 2- (47.5% vs. 31.7%; p = 0.038) or 4-cycle IC (47.5% vs. 36.2%; p = 0.039). Overall, the RPA-based model effectively stratified risk, guiding individualized IC cycle selection. Balancing toxicity and efficacy, 2-cycle IC is optimal for the low- and intermediate-risk groups, while 3-cycle IC is preferred for the high-risk group.

International Journal of Cancer
The First Affiliated Hospital, Sun Yat-sen University (CN), Sun Yat-sen University Cancer Center (CN), Guangzhou Medical University Cancer Hospital (CN), State Key Laboratory of Oncology in South China (CN), Guangzhou Medical University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation
Good health and well-being
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon